The Joint Annual Outcomes Brief
The co-branded outcomes report built into every Mamaya partnership. This is the template and methodology; each partner's edition is populated with their own de-identified cohort data.
Outcomes, reported back to the partner who referred them
Every Mamaya partnership includes a standing deliverable: a co-branded outcomes brief, produced on a regular cadence and co-authored with the partner. It answers one question plainly — what happened to the patients you sent us? — using the same measurement-based standard a payer or a clinical reviewer would expect.
This page is the template. The methodology below is fixed and applies to every partner. The figures shown as placeholders are populated from each partner's own de-identified cohort once it reaches a reportable size.
Who this brief covers
The cohort is every patient attributed to the partner — through a co-branded landing page, an embedded screener, a referral API, or a direct hand-off — who enrolled in a Mamaya service during the reporting period.
Did they actually get care?
Engagement is reported before outcomes, because an outcome only means something if the patient stayed long enough to have one. We report the share who activated, the share who completed an initial session or program module, and retention through the episode.
Did they get better?
Outcomes are reported as the field reports them: mean change from baseline, the share achieving clinical response (a reduction of 50% or more from the baseline score), and the share reaching remission (a score below the clinical threshold). Where the cohort is large enough, results are broken out by life stage so like is compared with like.
How the score is measured and tracked
Mamaya practices measurement-based care: the same validated instrument, administered at baseline and repeated on a fixed cadence, so change over time is real and comparable rather than impressionistic.
| Element | Standard |
|---|---|
| Instruments | PHQ-2 / PHQ-9 (depression), GAD-7 (anxiety), EPDS (perinatal). Life-stage-anchored where validated. |
| Baseline | Captured at enrollment, before the first working session. |
| Cadence | Re-administered at defined touchpoints — each assessment, program module, and care point across coaching, therapy, and medication management — and at discharge. |
| Tracking over time | Each patient is aligned to her own enrollment date; results are reported over a defined window (a rolling 12 months or the contract year). |
| Inclusion | A patient enters the outcome cohort once she has a baseline plus at least one follow-up measurement. |
| Outcome definitions | Mean change from baseline; response = a reduction of 50% or more; remission = a score below the clinical threshold. |
Which partners get which report
What a partner receives scales with cohort size — the number of referred patients with usable data, meaning a baseline plus at least one follow-up measurement.
Two floors apply. An 11-patient privacy floor, below which no partner-specific figure is ever published, because results drawn from a handful of women can identify them. And a higher reporting threshold — around 30 — below which a cohort is not yet stable enough to headline its own co-branded brief. Smaller cohorts still count: they roll into the pooled, de-identified aggregate until they clear it.
| Tier | Cohort | Deliverable |
|---|---|---|
| Anchor | Large, strategic partnerships | Bespoke, co-branded annual outcomes paper with the partner's own cohort data and joint authorship. |
| Established | Enough volume to be statistically meaningful | Standardized co-branded brief — this template, populated with the partner's numbers and logo. |
| Emerging | Below the reporting threshold (~30) | Included in the aggregate, de-identified reporting only, until volume clears the threshold. |
Strategic weight sets the format; cohort size sets what is reportable. Below the 11-patient privacy floor, nothing partner-specific is ever published; below the ~30 reporting threshold, a partner's patients are reported only in the aggregate.
Population-level and de-identified, by design
- —Population-level only — every figure describes a group, never an individual. The partner never sees patient-level data.
- —HIPAA de-identification — reporting meets the Safe Harbor standard (all 18 identifiers removed); published outcomes use Expert Determination, in which a qualified statistician certifies a low risk of re-identification.
- —Small-cell suppression — no statistic is reported for a cohort below the 11-patient privacy floor, and sparse cells are suppressed or combined.
- —Governed by agreement — the data-use terms, de-identification standard, and reporting cadence are written into the partnership agreement, with a business associate agreement where one applies.
This template is a co-branded deliverable, not a published claim. Each partner edition is reviewed by Mamaya's clinical team and the partner before release, and figures are final only once the cohort meets the reporting threshold described above.